What is William Blair’s Forecast for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Neurogene in a research report issued to clients and investors on Tuesday, March 25th. William Blair analyst S. Corwin anticipates that the company will earn ($1.18) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene’s Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($1.14) EPS and Q4 2026 earnings at ($1.16) EPS.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.05. The business had revenue of $0.93 million for the quarter.

Separately, HC Wainwright reduced their price target on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $59.80.

Neurogene Stock Performance

Shares of NASDAQ NGNE opened at $16.14 on Wednesday. The firm has a market cap of $239.76 million, a PE ratio of -3.78 and a beta of 1.01. Neurogene has a one year low of $13.47 and a one year high of $74.49. The firm has a fifty day moving average of $16.97 and a 200 day moving average of $29.06.

Insider Transactions at Neurogene

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the sale, the chief financial officer now directly owns 72,343 shares in the company, valued at $1,225,490.42. This represents a 5.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 9.92% of the company’s stock.

Hedge Funds Weigh In On Neurogene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Casdin Capital LLC increased its stake in shares of Neurogene by 146.9% in the 4th quarter. Casdin Capital LLC now owns 1,295,361 shares of the company’s stock worth $29,612,000 after acquiring an additional 770,745 shares during the last quarter. FMR LLC grew its holdings in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after purchasing an additional 659,515 shares during the period. JPMorgan Chase & Co. increased its position in Neurogene by 10,395.3% during the fourth quarter. JPMorgan Chase & Co. now owns 481,001 shares of the company’s stock worth $10,996,000 after purchasing an additional 476,418 shares during the last quarter. Samsara BioCapital LLC increased its position in Neurogene by 35.4% during the fourth quarter. Samsara BioCapital LLC now owns 1,717,127 shares of the company’s stock worth $39,254,000 after purchasing an additional 449,337 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new position in Neurogene during the fourth quarter worth about $10,245,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.